EUVIMEDEUVIMED entdecken
Crossref

Programable Prodrug Nanomodulator Targets Tumor Redox Homeostasis Imbalance to Amplify Disulfidptosis and Immunogenic Pyroptosis for Breast Tumor Immunotherapy

Ayeskanta Mohanty iD, Adityanarayan Mohapatra iD, Woojin Yang, Seunghyun Choi, Aravindkumar Sundaram iD, Yong-Yeon Jeong, Chang-Moon Lee, Jiwon Seo, In-Kyu Park iD

Advanced Healthcare Materials · 2025-04 · 14 (11)

DOI: 10.1002/adhm.202500272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 20.03.2025. Verfasst von Ayeskanta Mohanty und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, Gwangju, 61469, Repub…. Hauptthemen laut MEDLINE: Prodrugs, Pyroptosis, Immunotherapy, Breast Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the great potential of photodynamic therapy (PDT), its success remains compromised by the abnormal redox homeostasis of tumor cells, which supports survival, growth, and resistance to oxidative therapeutic interventions by neutralizing reactive oxygen species (ROS). To overcome this barrier, a multifunctional prodrug nanomodulator (Pro@FLNC) is designed to induce disulfidptosis and immunogenic pyroptosis to trigger an antitumor immune response. Pro@FLNC features a prodrug core–shell structure where ursolic acid (UA) and Chlorin e6 (Ce6) are conjugated via a GSH‐responsive linker and encapsulated in a DSPE‐PEG‐FA lipid shell for enhanced stability, biocompatibility, and tumor‐specific targeting. Within the tumor microenvironment (TME), Pro@FLNC depletes intracellular GSH, disrupts redox homeostasis, and releases Ce6 and UA, triggering oxidative stress and mitochondrial dysfunction. These mechanisms amplify ROS production, promote lipid peroxidation, and initiate disulfidptosis, evidenced by increased SLC7A11 expression and F‐actin collapse. Elevated ROS levels and metabolic imbalance‐triggered disulfidptosis further activate immunogenic pyroptosis, releasing damage‐associated molecular patterns (DAMPs) that stimulate dendritic cell maturation and cytotoxic T‐cell activation. Together, Pro@FLNC reshapes the TME, reduces immunosuppressive cells, and promotes CD8 + T‐cell infiltration, effectively suppressing primary tumors and metastases. This programmed prodrug nanomodulator offers a promising strategy to enhance PDT and immunotherapy for advanced breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsPyroptosisImmunotherapyBreast NeoplasmsNanoparticlesHumansFemaleAnimalsHomeostasisOxidation-ReductionMiceChlorophyllidesReactive Oxygen SpeciesCell Line, TumorTumor MicroenvironmentTriterpenesUrsolic AcidPorphyrinsPhotochemotherapyDisulfidptosis

Stichwörter der Autor:innen

breast tumor immunotherapydisulfidptosisphotodynamic therapy (PDT)prodrug nanoparticlepyroptosisreactive oxygen species (ROS)

Substanzen

ProdrugsChlorophyllidesReactive Oxygen SpeciesphytochlorinTriterpenesUrsolic AcidPorphyrins

Autor:innen und Institutionen

  • Department of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, Gwangju, 61469, Republic of Korea.
  • DR Cure Inc., Hwasun, 58128, Republic of Korea.
  • Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju, 61005, Republic of Korea.
  • Department of Radiology, Chonnam National University Medical School and Hwasun Hospital, 322 Seoyang-Ro, Hwasun-Gun, Jeollanam-do, 58128, Republic of Korea.
  • School of Healthcare and Biomedical Engineering, Chonnam National University, Yeosu, 59626, Republic of Korea.
  • Leading Research Center of Total Solution for Osteoporosis Treatment, Chonnam National University, Yeosu, 59626, Republic of Korea.

ORCID-Profile: Ayeskanta Mohanty, Adityanarayan Mohapatra, Aravindkumar Sundaram, In-Kyu Park

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Mohanty, A., Mohapatra, A., Yang, W., Choi, S., Sundaram, A., Jeong, Y. Y., Lee, C. M., Seo, J., & Park, I. K. (2025). Programable Prodrug Nanomodulator Targets Tumor Redox Homeostasis Imbalance to Amplify Disulfidptosis and Immunogenic Pyroptosis for Breast Tumor Immunotherapy. Advanced Healthcare Materials, 14(11). https://doi.org/10.1002/adhm.202500272

Vancouver

Mohanty A, Mohapatra A, Yang W, Choi S, Sundaram A, Jeong YY, et al. Programable Prodrug Nanomodulator Targets Tumor Redox Homeostasis Imbalance to Amplify Disulfidptosis and Immunogenic Pyroptosis for Breast Tumor Immunotherapy. Advanced Healthcare Materials. 2025;14(11). doi:10.1002/adhm.202500272

BibTeX
@article{Mohanty2025,
  author = {Mohanty, Ayeskanta and Mohapatra, Adityanarayan and Yang, Woojin and Choi, Seunghyun and Sundaram, Aravindkumar and Jeong, Yong-Yeon and Lee, Chang-Moon and Seo, Jiwon and Park, In-Kyu},
  title = {Programable Prodrug Nanomodulator Targets Tumor Redox Homeostasis Imbalance to Amplify Disulfidptosis and Immunogenic Pyroptosis for Breast Tumor Immunotherapy},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  volume = {14},
  number = {11},
  doi = {10.1002/adhm.202500272}
}
Kostenlos starten →